Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Am J Physiol Lung Cell Mol Physiol ; 315(1): L52-L58, 2018 07 01.
Article in English | MEDLINE | ID: mdl-29516781

ABSTRACT

Infection with seasonal influenza A virus (IAV) leads to lung inflammation and respiratory failure, a main cause of death in influenza-infected patients. Previous experiments in our laboratory indicate that Bruton's tyrosine kinase (Btk) plays a substantial role in regulating inflammation in the respiratory region during acute lung injury in mice; therefore, we sought to determine if blocking Btk activity has a protective effect in the lung during influenza-induced inflammation. The Btk inhibitor ibrutinib (also known as PCI-32765) was administered intranasally to mice starting 72 h after lethal infection with IAV. Our data indicate that treatment with the Btk inhibitor not only reduced weight loss and led to survival, but also had a dramatic effect on morphological changes to the lungs, in IAV-infected mice. Attenuation of lung inflammation indicative of acute lung injury, such as alveolar hemorrhage, interstitial thickening, and the presence of alveolar exudate, together with reduced levels of the inflammatory mediators TNFα, IL-1ß, IL-6, KC, and MCP-1, strongly suggests amelioration of the pathological immune response in the lungs to promote resolution of the infection. Finally, we observed that blocking Btk specifically in the alveolar compartment led to significant attenuation of neutrophil extracellular traps released into the lung in vivo and neutrophil extracellular trap formation in vitro. Our innovative findings suggest that Btk may be a new drug target for influenza-induced lung injury, and, in general, that immunomodulatory treatment may be key in treating lung dysfunction driven by excessive inflammation.


Subject(s)
Acute Lung Injury/enzymology , Agammaglobulinaemia Tyrosine Kinase/metabolism , Influenza A Virus, H1N1 Subtype/metabolism , Macrophages, Alveolar/enzymology , Orthomyxoviridae Infections/enzymology , Acute Lung Injury/drug therapy , Acute Lung Injury/pathology , Acute Lung Injury/virology , Adenine/analogs & derivatives , Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Animals , Cytokines/metabolism , Extracellular Traps/metabolism , Macrophages, Alveolar/pathology , Mice , Orthomyxoviridae Infections/pathology , Piperidines , Protein Kinase Inhibitors/pharmacology , Pyrazoles/pharmacology , Pyrimidines/pharmacology
2.
J Autism Dev Disord ; 33(4): 427-33, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12959421

ABSTRACT

Studies of the broader autism phenotype, and of subtle changes in autism symptoms over time, have been compromised by a lack of established quantitative assessment tools. The Social Responsiveness Scale (SRS-formerly known as the Social Reciprocity Scale) is a new instrument that can be completed by parents and/or teachers in 15-20 minutes. We compared the SRS with the Autism Diagnostic Interview-Revised (ADI-R) in 61 child psychiatric patients. Correlations between SRS scores and ADI-R algorithm scores for DSM-IV criterion sets were on the order of 0.7. SRS scores were unrelated to I.Q. and exhibited inter-rater reliability on the order of 0.8. The SRS is a valid quantitative measure of autistic traits, feasible for use in clinical settings and for large-scale research studies of autism spectrum conditions.


Subject(s)
Asperger Syndrome/diagnosis , Autistic Disorder/diagnosis , Child Development Disorders, Pervasive/diagnosis , Personality Inventory/statistics & numerical data , Social Behavior , Asperger Syndrome/psychology , Autistic Disorder/psychology , Child , Child Development Disorders, Pervasive/psychology , Child, Preschool , Female , Humans , Male , Psychometrics , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL